Sotherly Hotels Stock (NASDAQ:SOHOO), Trade Ideas

Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.

Sotherly Hotels Inc. - 7.875% Series C Cumulative Redeemable Perpetual Preferred Stock

Sotherly Hotels Inc

News

Guidance

COLD

Americold Realty Trust Sees FY24 AFFO $1.38-$1.46

TELA

TELA Bio Increases FY24 Revenue Guidance From $74M-$76M To $74.5M-$76.5M, Est $74.94M

Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 216.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $10.663 million which beat the analyst consensus estimate of $4.120 million by 158.81 percent. This is a 212.33 percent increase over sales of $3.414 million the same period last year.

Earnings

Earnings Beats

SRTS

Sensus Healthcare Q1 2024 GAAP EPS $0.14 Beats $(0.06) Estimate, Sales $10.663M Beat $4.120M Estimate

Dividends

Pembina Pipeline Increases Quarterly Dividend By 3.4% To C$0.69/Share

Dropbox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBX#NASDAQ">DBX</a>) reported its first-quarter financial results after the bell Thursday. Here's a <a href="https://www.benzinga.com/pressreleases/24/05/b38743108/dropbox-announces-fiscal-2024-first-quarter-results">look at the highlights. </a>
The Details: Dropbox reported quarterly earnings of 58 cents per share which beat the analyst consensus estimate of 50 cents by 16%. Quarterly sales came in at $631.3 million which beat the analyst consensus estimate of $628.67 million and is a 3.31% increase over sales of $611.1 million from the same period last year.
Dropbox reported 18.16 million paying users for the quarter, as compared to 17.9 million for the same period last year. Paying users increased by 35,000 quarter-over-quarter. Average revenue per paying user was $139.59, as compared to $138.97 for the same period last year.
Total annual recurring revenue (ARR) was $2.556 billion in the first quarter, an increase of 3.6% from the same period last year.
Non-GAAP gross margin was 84.6%, as compared to 82.4% for the same period last year.
&#8220;In Q1, our core business delivered in-line revenue and better than anticipated profitability,&#8221; said Dropbox CEO Drew Houston. &#8220;We recently announced a collection of product updates designed to make it even easier for our users to secure, organize and share their content across different devices, locations and platforms. Looking ahead, we&#8217;ll stay disciplined in our operations, while investing in growth initiatives focused on building AI powered product experiences to improve distributed work for our customers.&#8221;
DBX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Dropbox shares are up 1.99% after-hours at $23.60 at the time of publication Thursday.
Related News:<a href="https://www.benzinga.com/news/24/05/38741220/whats-going-on-with-pelotons-stock"> What&#8217;s Going On With Peloton&#8217;s Stock?</a>
Photo: Shutterstock

After-Hours Center

Movers

Dropbox Shares Rise On Better-Than-Expected Q1 Results

American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) ("the Company", "American Coastal" or "ACIC"), the insurance holding company of Interboro Insurance Company ("Interboro"), a New York domiciled insurance company, announced today that it has signed definitive agreements with Forza Insurance Holdings, LLC ("Forza") in which ACIC will sell and Forza will acquire 100% of the issued and outstanding stock of Interboro. Closing is subject to the approval of the New York Department of Financial Services. The transaction completes the run-off of ACIC's personal lines portfolio and allows ACIC to focus on its fast-growing commercial specialty property portfolio.
Concurrently, Interboro and SageSure entered into a Program Administrator Agreement and a Claims Services Agreement on May 9, 2024. Under the terms of these service agreements, SageSure will provide policy administration, underwriting and claims administration services on behalf of Interboro.

Asset Sales

ACIC

American Coastal Insurance Announces The Sale Of 100% Of The Issued And Outstanding Stock Of Interboro Insurance To Forza Insurance; Financial Terms Of The Transaction Not Disclosed

Scripps Raises FY24 Election-Year Political Advertising Revenue From $210M-$250M To $240M-$270M

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.45 by 11.11 percent. This is a 13.04 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $95.613 million which missed the analyst consensus estimate of $99.817 million by 4.21 percent. This is a 0.20 percent decrease over sales of $95.801 million the same period last year.

Earnings Misses

Karat Packaging Q1 2024 Adj EPS $0.40 Misses $0.45 Estimate, Sales $95.613M Miss $99.817M Estimate

Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.24) by 16.94 percent. This is a 19.44 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $25.235 million which missed the analyst consensus estimate of $29.535 million by 14.56 percent. This is a 43.14 percent decrease over sales of $44.383 million the same period last year.

SKLZ

Skillz Q1 2024 GAAP EPS $(1.45) Misses $(1.24) Estimate, Sales $25.235M Miss $29.535M Estimate

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 66 percent increase over losses of $(0.50) per share from the same period last year.

BEAT

HeartBeam Q1 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate

Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.25) by 24 percent. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $70.503 million which missed the analyst consensus estimate of $82.632 million by 14.68 percent. This is a 9.08 percent decrease over sales of $77.541 million the same period last year.

FTHM

Fathom Holdings Q1 2024 GAAP EPS $(0.31) Misses $(0.25) Estimate, Sales $70.503M Miss $82.632M Estimate

Farmer Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.16) by 81.25 percent. This is a 91.18 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $85.358 million which missed the analyst consensus estimate of $88.500 million by 3.55 percent. This is a 0.43 percent decrease over sales of $85.723 million the same period last year.

FARM

Farmer Bros Q3 2024 GAAP EPS $(0.03) Beats $(0.16) Estimate, Sales $85.358M Miss $88.500M Estimate

ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.

SPRY

ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11), Inline

MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.15) by 246.67 percent. This is a 1633.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $9.000 million which beat the analyst consensus estimate of $7.000 million by 28.57 percent. This is a 10.00 percent decrease over sales of $10.000 million the same period last year.

MBIA Q1 2024 Adj EPS $(0.52) Misses $(0.15) Estimate, Sales $9.000M Beat $7.000M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) reported quarterly earnings of $0.03 per share. This is unchanged from the same period last year. The company reported quarterly sales of $97.337 million which missed the analyst consensus estimate of $97.557 million by 0.23 percent. This is a 0.37 percent decrease over sales of $97.698 million the same period last year.

BRLT

Brilliant Earth Group Q1 2024 adjusted EPS $0.03, Same YoY, Sales $97.337M Miss $97.557M Estimate

AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer
HAMILTON, ON and BOSTON, May 9, 2024 /CNW/ --&nbsp;Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSN#NASDAQ">FUSN</a>), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&amp;T)&nbsp;in patients with&nbsp;metastatic castration-resistant prostate cancer (mCRPC).
"Actinium-based PSMA targeting RCs have demonstrated compelling safety and clinical activity, which is supported by Fusion's encouraging data from the Phase 2 TATCIST trial reported recently at the AACR Annual Meeting. We believe FPI-2265 represents an important potential new treatment option for patients with mCRPC, and with the initiation of the AlphaBreak trial we are pleased to move forward," said Chief Medical Officer Dmitri Bobilev, M.D.
"Despite recent advances in the field, we see many patients with mCRPC still in need of additional treatment options, especially after progressing on lutetium-based radiotherapy. It is encouraging to see the promising clinical activity and good safety profile demonstrated by FPI-2265. The initiation of the AlphaBreak trial brings us a step closer to addressing the gap for patients and providing this needed treatment option," said investigator Luke Nordquist, M.D., FACP, XCancer Chief Executive Officer.
The AlphaBreak trial is a Phase 2/3, randomized, open-label, multicenter study to evaluate the safety and efficacy of FPI-2265 in patients with mCRPC previously treated with 177Lu-PSMA radiotherapy. The Phase 2 dose optimization portion is designed to evaluate whether there are added safety and/or efficacy benefits of two alternative dosing regimens in comparison to the previously studied regimen of 100 kBq/kg every eight weeks. The Phase 2 portion of the AlphaBreak trial is expected to complete enrollment of approximately 60 patients by the end of 2024. Following analysis of the Phase 2 data and an end of Phase 2 meeting to determine the recommended Phase 3 dosing regimen with the U.S. Food and Drug Administration (FDA), the Phase 3 global registration portion of the AlphaBreak trial will enroll approximately 550 patients and is expected to begin in 2025.

Biotech

General

FUSN

Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.46) by 17.39 percent.

ETNB

89bio Q1 2024 GAAP EPS $(0.54) Misses $(0.46) Estimate

Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 13.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $230.000 thousand which missed the analyst consensus estimate of $585.000 thousand by 60.68 percent. This is a 5.65K percent increase over sales of $4.000 thousand the same period last year.

CLSD

Clearside Biomedical Q1 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $230.000K Miss $585.000K Estimate

FNKO

Funko Sees Q2 2024 Adj. EPS $(0.15)-$(0.08) Vs $(0.21) Est.; NEt Sales $225M-$240M Vs $230.147M Est.

<div>Targeting operational efficiencies, providing a Company gross margin target of&nbsp;20%&nbsp;to&nbsp;25% for Q2.</div>

MVST

Microvast Sees Q2 Revenue Growth Of 20%-30% Y/Y To $90M-$98M, Est $74.309M

Sotherly Hotels Inc. 7.875% PFD SER C declares $0.4922 dividend

Goldilocks Is Back

Sotherly Hotels, Inc. (SOHO) Q2 2023 Earnings Call Transcript

Sotherly Hotels Inc. (SOHO) Q3 2023 Earnings Call Transcript

Sotherly Hotels Inc. 7.875% PFD SER C goes ex dividend tomorrow

Sotherly Hotels Inc. 7.875% PFD SER C declares $0.492 dividend

Sotherly Hotels Inc. 7.875% PFD SER C goes ex dividend today

Sotherly Hotels Inc. (SOHO) Q4 2023 Earnings Call Transcript

Sotherly Hotels, Inc. (SOHO) Q1 2024 Earnings Call Transcript

AAIC

AAIN

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

AMZN

BLDG

BXMT

CTRE

CUBE

DBRG

DISH

EQIX

EWRE

FREL

GPMT

GQRE

HASI

HAUS

HAUZ

HOMZ

IFGL

INDS

INVH

KBWY

LADR

LAND

LANDM

LANDO

MORT

NAIL

NETL

NURE

NVDA

PFFR

PLDGP

PPTY

RDOG

REET

REIT

RESI

RIET

ROOF

SBAC

SCHH

SOHO

SOHOB

SOHON

SOHOO

SRVR

STWD

TMUS

TRTX

USRT

VRAI

WELL

XLRE

Ashford Hospitality Trust Inc Common Stock

Ashford Hospitality Trust

Apple Hospitality REIT, Inc. Common Shares

Apple Hospitality REIT

Braemar Hotels & Resorts Inc. Common Stock

Braemar Hotels & Resorts

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging

Diamondrock Hospitality Company Common Stock

Diamondrock Hospitality

Host Hotels & Resorts, Inc. - Common Stock

Host Hotels & Resorts

InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality

Summit Hotel Properties, Inc. Common Stock

Summit Hotel Properties

Pebblebrook Hotel Trust Common Shares of Beneficial Interest

Pebblebrook Hotel

Park Hotels & Resorts

Ryman Hospitality Properties, Inc. (REIT)

Ryman Hospitality Props

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

RLJ Lodging

Sunstone Hotel Investors, Inc. Sunstone Hotel Investors, Inc. Common Shares

Sunstone Hotel Invts

Sotherly Hotels

Service Properties Trust - Shares of Beneficial Interest

Service Properties Trust

Xenia Hotels & Resorts, Inc. Common Stock

Xenia Hotels & Resorts